Sarepta Therapeutics, Inc. appears largely unfazed by recent controversies that have beset its Roche Holding AG-partnered Duchenne muscular dystrophy (DMD) gene therapy candidate, SRP-9001, with commercial activities underway for an anticipated launch later this month pending a US Food and Drug Administration advisory committee meeting.
During its Q1 earnings, the firm claimed it could become profitable as soon as next year on the condition that SRP-9001 wins accelerated approval in the US
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?